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Short hairpin RNA (shRNA) technology enables sta-
ble and regulated gene repression. For establishing
experimentally versatile RNAi tools and minimizing
toxicities, synthetic shRNAs can be embedded into
endogenous microRNA contexts. However, due to
our incomplete understanding of microRNA biogen-
esis, such ‘‘shRNAmirs’’ often fail to trigger potent
knockdown, especially when expressed from a
single genomic copy. Following recent advances in
design of synthetic shRNAmir stems, here we take
a systematic approach to optimize the experimental
miR-30 backbone. Among several favorable fea-
tures, we identify a conserved element 30 of the basal
stem as critically required for optimal shRNAmir
processing and implement it in an optimized back-
bone termed ‘‘miR-E’’, which strongly increases
mature shRNA levels and knockdown efficacy.
Existing miR-30 reagents can be easily converted
tomiR-E, and its combination with up-to-date design
rules establishes a validated and accessible platform
for generating effective single-copy shRNA libraries
that will facilitate the functional annotation of the
genome.INTRODUCTION
RNAi is an evolutionarily conservedmechanism of posttranscrip-
tional gene regulation that uses small RNAs produced through
multicomplex machinery to guide suppression of comple-
mentary transcripts. The most well-characterized endogenous
RNAi triggers, microRNAs (miRNAs), are expressed as hairpin-
like structures in primary transcripts (pri-miRNAs), recognized
and released as precursor miRNAs (pre-miRNAs) by the Drosha/
DGCR8 microprocessor complex, and further processed in the
cytoplasm by the Dicer/TRBP complex into mature small RNA
duplexes, of which one strand serves as guide to downregulate
complementary transcripts (for review, see Bartel, 2004; Car-
thew and Sontheimer, 2009; Filipowicz et al., 2008). Simulta-1704 Cell Reports 5, 1704–1713, December 26, 2013 ª2013 The Autneous to the discovery and ongoing exploration of miRNA
pathways, synthetic RNAi triggers have been developed to
experimentally program the RNAi machinery for loss-of-function
genetics. Beyond transfection of small interfering RNAs
(siRNAs), providing an efficient approach for transient gene
knockdown, short hairpin RNAs (shRNAs) can be expressed
from DNA vectors that enable stable and regulated loss-of-func-
tion studies in a gene-by-gene or pool-based format (for review,
see Hannon and Rossi, 2004; Mohr and Perrimon, 2012).
Among numerous existing shRNA reagents (for review, see Hu
and Luo, 2012; Pan et al., 2012), two basic expression systems
need to be distinguished. Simple stem-loop shRNAs transcribed
from Pol-III promoters enter the processing machinery at the
level of Dicer and can be effective RNAi triggers. However, their
enforced expression can saturate endogenousmiRNA pathways
and result in severe toxicities (Grimm et al., 2006). Moreover,
recent studies reveal that Dicer is imprecise in processing
commonly used stem-loop designs, which increases the likeli-
hood of aberrant guide- and passenger-strand mediated off-
target effects (Gu et al., 2012). An alternative approach is based
on embedment of synthetic shRNA stems into the context
of endogenous miRNAs. The resulting ‘‘shRNAmir’’ structures
serve as natural substrates in miRNA biogenesis pathways and
can trigger potent knockdown, as has been demonstrated for
a number of miRNA backbones, including miR-30, miR-155,
and miR17-92 (Chung et al., 2006; Liu et al., 2008; Zeng et al.,
2002).
Although studies comparing knockdown efficacies of simple
stem-loop and miRNA-embedded shRNAs have reported con-
flicting results (Boden et al., 2004; Boudreau et al., 2008; Silva
et al., 2005), shRNAmir-based systems offer several technical
advantages: (1) Like endogenous miRNAs, shRNAmirs can be
expressed from Pol-II promoters, which has enabled tissue-spe-
cific RNAi studies (Hinterberger et al., 2010) as well as the devel-
opment of robust tetracycline (Tet)-regulated RNAi systems
(Dickins et al., 2005; Stegmeier et al., 2005); (2) in Pol-II tran-
scripts, shRNAmirs can be placed in the 30 UTR of a reporter
to directly monitor shRNA expression (Premsrirut et al., 2011;
Stegmeier et al., 2005; Zuber et al., 2011a); (3) like miRNAs, mul-
tiple shRNAmirs can be expressed as a polycistron, providing a
setup for combinatorial RNAi studies (Chung et al., 2006; Zhu
et al., 2007); (4) shRNAmirs are less prone to cause toxicities
by interfering with endogenous miRNA pathways (Boudreauhors
et al., 2009; Castanotto et al., 2007; McBride et al., 2008; Pre-
msrirut et al., 2011); and (5) the natural loop configuration of
shRNAmirs such as miR-30 complies with a recently discovered
‘‘loop-counting rule’’ (Gu et al., 2012) that ensures precise Dicer
cleavage and reduces off-target effects.
The key limitation of existing shRNAmir reagents is our inability
to predict shRNAs that trigger potent target knockdown (>80%
reduction in protein expression) when expressed from a single
genomic integration. Although such single-copy efficiency is a
critical prerequisite for various key applications such as pool-
based RNAi screening and transgenic RNAi, shRNA reagents
are typically untested at this stringency level. In fact, until
recently, shRNAmir design strategies were mainly based on
siRNA data sets, and many previous studies evaluating
shRNAmir constructs were solely based on plasmid DNA trans-
fection (Chung et al., 2006; Silva et al., 2005; Zeng et al., 2002),
which fails to reflect the relevant single-copy setting (Fellmann
et al., 2011). At the same time, our still limited understanding of
structural requirements for effective miRNA biogenesis hampers
the rational optimization of shRNAmir reagents.
In an effort to functionally identify highly effective miR-30-
based shRNAs, and systematically explore shRNA processing
requirements, we have recently established an RNAi Sensor
assay able to measure knockdown potency of thousands of
shRNAs at single-copy conditions in a pooled format (Fellmann
et al., 2011). Our study revealed that potent single-copy shRNAs
are rare and share distinct sequence features that can be asso-
ciated with specific miRNA biogenesis steps. Notably, the most
potent shRNAs were also characterized by a marked bias for
incorporating the guide strand, suggesting that the use of these
shRNAs will not only boost on-target knockdown levels, but also
reduce passenger-mediated off-target effects. Beyond these
advances in identifying single-copy effective shRNAs, results
from this and a parallel study (Premsrirut et al., 2011) indicated
that single-copy expression of even the most potent shRNAs re-
sults in mature small RNA levels well below the most abundant
endogenous miRNAs, raising the possibility that miR-30-based
RNAi reagents could be further improved by optimizing the
miRNA scaffold. To explore this option, here we systematically
evaluate how conserved sequence features in the miR-30 back-
bone impact the potency of shRNAmirs under strict single-copy
conditions. Among several improved design variants, the most
potent (termed ‘‘miR-E’’) incorporates a conserved sequence
element 30 of the basal stem and can easily be implemented in
existing miR-30 reagents to globally enhance mature small
RNA production and knockdown potency.
RESULTS
Although many key players in miRNA biogenesis are known, our
understanding of substrate RNA sequence features required for
effective pri- and pre-miRNA processing is still limited (Chiang
et al., 2010), hampering the rational optimization of shRNAmir
backbones. Because conserved sequence elements in pri-
miRNAs can impact miRNA biogenesis (Feng et al., 2011; Han
et al., 2006), we examined whether any such elements have
been altered in the experimental miR-30 backbone. Compared
to the natural human MIR30A, the common miR-30 backboneCell Rediffers in three potentially relevant features (Figures 1A and
S1A): (1) The synthetic miR-30 stem has no bulge and harbors
the intended guide on the opposite strand; (2) for designing the
30 overhangs of synthetic shRNAs, two conserved base pairs
flanking the loop were changed from CU/GG to UA/UA; and (3)
the introduction of XhoI/EcoRI restriction sites for shRNA cloning
led to a mutation in a highly conserved region 30 of the basal
stem.
To investigate the impact of these alterations on shRNAmir
knockdown efficiency, we designed 11 miR-30 variants that
revert each feature individually or in combination back to the
endogenous MIR30A configuration (Figure S1B). As experi-
mental shRNA for these studies, we selected a previously char-
acterized intermediate Pten shRNA (Pten.1524, 62% protein
knockdown at single copy) (Fellmann et al., 2011), whose target
site lies directly adjacent to that of a highly potent Pten shRNA
(Pten.1523, 96% knockdown), which makes it unlikely that the
limited potency of Pten.1524 is due to target site inaccessibility
(Ameres et al., 2007). To test the knockdown potential of different
backbone variants harboring Pten.1524, we employed a newly
developed fluorescence-based reporter assay that enables
accurate quantification of single-copy protein knockdown levels
of up to 20 experimental and several control shRNAs side by side
(Figures S1C–S1F).
Compared to potent control shRNAs, Pten.1524 in the com-
mon miR-30 configuration produced intermediate knockdown
levels (Figure 1B). Although several miR-30 variants involving
bulges and reversed stem configurations had no or a negative
impact, four designs significantly enhanced reporter knockdown
(p < 0.001). Strikingly, two of the tested alternative backbones
increased the knockdown potency of Pten.1524 to levels in
the range of our most potent control shRNAs. One of them,
miR-R1B1, was designed to closely resemble the stem-loop
structure of the endogenous MIR30A, whereas the other config-
uration, termed ‘‘miR-E’’, restores conserved sequence features
30 of the basal stem by repositioning the EcoRI cloning site to a
nonconserved region further 30 and modifying the 50 miR-30
scaffold opposing EcoRI in a way that minimizes changes to
the overall secondary structure (Figures S1B and S1G).
Although both miR-R1B1 and miR-E boosted knockdown to a
similar degree, we decided to focus our subsequent analyses on
miR-E, because existing miR-30 reagents and methodology can
be easily adapted to this design, whereas the implementation of
miR-R1B1 would require de novo shRNA cloning and revision of
many established protocols. Moreover, in a reversed passenger-
guide configuration, the critical 50 end of the guide strand would
not be determined by Dicer, which is known to cleave miR-30 at
the intended site with 98% accuracy (Gu et al., 2012), but by the
microprocessor complex, which appeared to be less precise in
our previous analyses (Fellmann et al., 2011).
To confirm the strong effects of miR-E, we transduced NIH
3T3 fibroblasts under single-copy conditions with our potent
and intermediate Pten shRNAs in conventional miR-30, miR-E,
and an ineffective reversed stem configuration and analyzed
Pten knockdown using western blotting (Figure 1C). Again, the
miR-E design dramatically improved the potency of Pten.1524,
and even for Pten.1523 enhanced target knockdown. To test
whether the miR-E design could be further improved, weports 5, 1704–1713, December 26, 2013 ª2013 The Authors 1705
A B
C
Pol-II GFP
shRNAmir
X E
Conserved
A
G
A
A
A
G
G
C
UC
A
G A
A
G
G
U A
U
A
U
U
C
A
G
U
G
A
G
C
G
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
U
A
GUG
AA
G
C C A C
A G A
U
G
U
A
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
U
G
C
C
U
A
C
U
G
G
A C
C
U U C G G A U U C A A GUA A C C C A A C G C U GGG G U U G G G C U A C U U U A G G A
miR-30
A
A
A
G
G
C
UA
A
A
G A
A
G
G
U A
U
A
U
U
C
A
G
U
G
A
G
C
G
A
C
U
G
U
A
A
A
C
A
U
C
C
G
A
C
U
G
G
A
A
G
C
U
GUG
AA
G
C C A C
A G A
U
G
G
G
C
U
U
U
C
A
G
U
C
G
G
A
U
G
U
U
U
G
C
A
G
C
U
G
C
C
U
A
C
U
G
G
A C
C
U U C G G A C U U C A A GUA A C C C A A C G C U GGG G U U G G G C U A C U U U A G G A
U
C
Endo MIR30A
Stem
Loop
Basal
stem
Guide
XhoI
EcoRI
100
80
60
40
20
0
E
m
pt
y
R
en
.7
13
P
te
n.
15
23
[P
te
n.
15
24
]
L 
(e
nd
o 
lo
op
)
B
1 
(b
ul
ge
 1
)
B
2 
(b
ul
ge
 2
)
L+
B
1
L+
B
2
R
1 
(r
ev
er
se
 1
)
R
2 
(r
ev
er
se
 2
)
R
1B
1 
(R
1 
+ 
bu
lg
e 
1)
R
2B
1 
(R
2 
+ 
bu
lg
e 
1)
R
2B
2 
(R
2 
+ 
bu
lg
e 
2)
E
 (3
’ f
la
nk
 a
t E
co
R
I)
R
ep
or
te
r k
no
ck
do
w
n 
[%
]
p = 0.0002
*
* *
*
Day 3
Day 6
Actin
Pten (short)
R
en
.7
13
P
te
n.
15
23
P
te
n.
15
24
P
te
n.
15
23
P
te
n.
15
24
P
te
n.
15
23
P
te
n.
15
24
Pten (long)
miR-30 miR-R2 miR-E
R
ep
or
te
r k
no
ck
do
w
n 
[%
] 100
80
60
40
20
0
-20
E
m
pt
y
R
en
.7
13
[P
te
n.
15
24
] L
R
1B
1
R
2B
2 E
E
+L
E
+R
1B
1
E
+R
2B
2
miR-EmiR-30
Day 3
Day 6
D
Figure 1. Evaluation of Structural Variants of the Common miR-30 shRNAmir Backbone
(A) Comparison of sequence and predicted structure of the endogenous human MIR30A (black) and the experimental miR-30 backbone (blue). In MIR30A,
conserved nucleotides (see Figure S1A for details) are printed in dark red, the guide strand (miR-30a-5p) is highlighted in yellow, and a conserved region 30 of the
basal stem is underlined. In the experimental miR-30, variable target dependent nucleotides are shown as ‘‘N’’, the guide strand is highlighted in yellow, restriction
sites used for shRNA cloning are highlighted in blue, and all conserved nucleotides that are altered compared to MIR30A are printed in red. Arrows indicate
canonical Drosha and Dicer cleavage sites.
(B) Reporter-based evaluation of shRNAmir backbone variants. Reporter cells expressing dTomato tagged with target sites of the probed shRNAs were
transduced at single copy with LMN vectors expressing the indicated shRNAs. All tested backbone variants (Figure S1B) contain Pten.1524. dTomato fluo-
rescence intensity of shRNA-expressing cells was quantified at the indicated time points (see Figures S1C–S1F for details). Values represent means of biological
triplicates; error bars represent the SEM. Asterisks, backbone variants that show a highly significant (p < 0.001) increase in knockdown potency at day 6
compared to miR-30 Pten.1524.
(C) Immunoblotting for Pten in NIH 3T3 fibroblasts expressing the indicated shRNAs from miR-30, miR-R2, or miR-E under single-copy conditions (see Fig-
ure S1G for details). Short and long exposures are shown; miR30-based Ren.713 served as negative control.
(D) Reporter-based evaluation of backbone features in combination. Stem-loop features resulting in significantly improved knockdown (L, R1B1 and R2B2
in B) were tested side by side in the conventional miR-30 backbone or with the miR-E feature. Values are means of biological triplicates; error bars represent
the SEM.
See also Table S1 and Figure S1.
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constructed miR-E variants harboring the other three modifica-
tions found to increase miR-30 knockdown in our initial analysis
(Figures 1B and S1B). Although all three modifications again
enhanced knockdown of miR-30-based Pten.1524, none of
them was able to further improve the potent effects of the
miR-E design (Figure 1D). Together, these results illustrate that
the effectiveness of miRNA-based shRNAs can be strongly
enhanced by optimizing the shRNAmir backbone and reveal
one particularly powerful miR-30 design variant that can easily
be implemented in established reagents.
Following these initial studies, we explored whether the miR-E
design would enhance the knockdown potency of other shRNAs
and in other contexts. To this end, we converted a panel of
previously tested Mcl1, Bcl2, and Pten shRNAs of different
strengths to the new format and evaluated their potency in
miR-30 and miR-E side by side (Figures 2A–2C). In almost all
cases, the miR-E design resulted in a marked increase in
single-copy knockdown and (similar to Pten.1524) turned
various intermediate shRNAs into potent RNAi triggers. Beyond
studies in fibroblasts, we also evaluated our panel of Pten
shRNAs in other murine cell types, including immortalized hepa-
tocytes (BNL CL.2), endothelial cells (SVEC4-10), and kidney
cells (TCMK-1) (Figure 2C). The knockdown improvements
associated with miR-E were comparable in all four cell lines,
demonstrating that these effects are not restricted to specific
cell contexts. To explore whether these effects extend to non-
mammalian vertebrates, we also tested our two Pten shRNAs
using a reporter assay in chicken embryonic fibroblasts and
observed similar improvements with miR-E (Figure S2A).
Although these data illustrate that miR-E can result in dramatic
improvements of intermediate shRNAs, it remained less clear
how substantial these effects would be in case of already vali-
dated potent miR-30 shRNAs. Because in these cases protein
knockdown quantitation may underestimate the biological
importance of improvements in shRNAmir design, we explored
this question using functional assays. Specifically, we generated
miR-E versions of seven validated shRNAs targeting genes
known to be required for survival of MOLM-13 acute myeloid
leukemia (AML) cells (Zuber et al., 2011b, 2011c) and tested their
effects in competitive proliferation assays bymonitoring the rela-
tive fraction of cells expressing the shRNA-linked fluorescence
reporter (Figures 2D, S2B, and S2C). Strikingly, use of the
miR-E backbone led to more rapid depletion of shRNA-express-
ing AML cells in all seven cases, demonstrating that even
established potent miR-30 shRNAs can be enhanced through
conversion to themiR-E design. At the same time, an established
potent control shRNA targeting Renilla Luciferase (Ren.713)
(Zuber et al., 2011a) had no effects in miR-30 or miR-E (Figures
2E and S2C), indicating that use of themiR-E backbone does not
result in general toxicities.
To explore whether miR-E would generally improve the single-
copy potency of shRNAs cloned de novo based on up-to-date
design rules (Dow et al., 2012; Fellmann et al., 2011), we tested
11 predictions targeting Dnmt3a in miR-30 and miR-E using our
reporter assay. Although in miR-30 these new designs produced
variable knockdown effects and only two highly potent shRNAs
in the range of Ren.713, the miR-E format improved knockdown
potency and triggered >80% single-copy knockdown in all 11Cell Recases (Figures 2F and S2D–S2F). Similar results have been
observed for more than 50 shRNAs targeting other genes (data
not shown), whereas we have yet to encounter a single case
where implementing the miR-E design has a negative impact.
Of note, several of the enhanced shRNAs (i.e., Mcl1.1334,
Mcl1.1792, Mcl1.2018, MYC.1834) have previously been identi-
fied through systematic testing of every possible target site
(Fellmann et al., 2011), illustrating that miR-E can even boost
knockdown of the most potent miR-30 shRNAs. Together, these
results validate miR-E as a superior backbone for single-copy
miRNA-based RNAi.
Although miR-E differs from the previous miR-30 design
in several nucleotides (Figure S1G), we hypothesized that
restoring the conserved region 30 of the basal stem (Figure 1A)
provided the decisive feature for its improved function. To
explore this region in more detail, we constructed miR-E-
Pten.1524 variants carrying single point mutations in each of
eight consecutive nucleotides in this region and tested their
single-copy knockdown efficiency using two independent
assays (Figures 3A and 3B). Point mutations in three conserved
nucleotides severely impaired the knockdown potency of
miR-E to or even below levels observed using the miR-30
design. Mutations in three additional positions resulted in a
potency reduction that was only detected by western blot
analysis, whereas the only two positions completely unaffected
by mutation were nonconserved. Together, these results reveal
that the potent effects of miR-E crucially depend on the pres-
ence of a conserved -ACNNC- motif 30 of the basal stem,
whereas the other three conserved nucleotides (adding up to
an -ACNUCAA- motif) may also contribute to its optimal func-
tion. Interestingly, endogenous miRNAs show a propensity for
ACNNC/GCNNC/UCNNC motifs in the 30 flank (Figure 3C),
and the presence of these motifs correlates with high mature
miRNA levels (Figure S3B), suggesting that a 30 (non-C)CNNC
motif is a common miRNA feature associated with optimal
miRNA biogenesis.
Besides the position of this feature in the 30 backbone flank,
two observations strongly suggested that miR-E results in
increased knockdown levels due to enhanced pri-miRNA pro-
cessing. First, compared to miR-30, single-copy expression of
transcripts encoding GFP and miR-E shRNAs resulted in signif-
icantly lower GFP fluorescence levels (Figure 3D), indicating that
a larger fraction of these transcripts are recognized and pro-
cessed as pri-miRNAs and thus no longer available for reporter
protein expression (Figure 3E). Second, presumably for similar
reasons, packaging of miR-E containing retroviruses yields
significantly lower virus titers, leading to reduced infection effi-
ciencies (Figure S3C). To test this hypothesis, we performed
cotransfection assays using siRNAs targeting Microprocessor
components and a dual-color reporter vector expressing GFP-
coupled miR-30 or miR-E shRNAs alongside a secondary
mCherry transcript to control for transfection efficiency. Again,
use of miR-E resulted in strongly reduced GFP expression levels
compared to miR-30, whereas in both cases siRNA-mediated
suppression of DROSHA or DGCR8 resulted in a significant
increase in GFP expression to similar levels (Figure S3D).
Together, these data indicate that the superior knockdown
potential of miR-E-based shRNAs is due to enhanced pri-miRNAports 5, 1704–1713, December 26, 2013 ª2013 The Authors 1707
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Figure 2. Validation of the miR-E Backbone
(A and B) (A) Bcl2 and (B)Mcl1 western blotting in NIH 3T3 cells transducedwith LMP expressing the indicated shRNAs from either themiR-30 ormiR-E backbone
at single copy (see also Table S1).
(C) Comparison of Pten knockdown in fibroblasts (NIH 3T3), immortalized hepatocytes (BNL CL.2), endothelial cells (SVEC4-10), and kidney cells (TCMK-1)
transduced at single copy with LMP expressing the indicated shRNAs from either the miR-30 or miR-E backbone (see also Figure S2A).
(D) Competitive proliferation assays evaluating established shRNAs targeting genes known to be essential in MOLM-13 leukemia cells. Tet-ON competent
MOLM-13 cells were infected with a vector conditionally expressing the indicated shRNAs from the miR-30 or miR-E backbone. Infected cells were mixed with
uninfected cells, and the percentage of shRNA expressing cells monitored upon shRNA induction by doxycycline (dox) (see also Figure S2B).
(E) Same competition assay as in (D), run with a neutral control shRNA (Ren.713). Note, no cytotoxic nor cytostatic effects were observed for neither miR-30 nor
miR-E (see also Figure S2C).
(F) Reporter-based quantification of knockdown efficiency of various Dnmt3a shRNAs expressed from either the miR-30 or miR-E backbone under single-copy
conditions. Mouse embryonic fibroblasts expressing a dTomato reporter tagged with target sites of the probed shRNAs were transduced at single copy with the
indicated shRNAs. An empty vector, Ren.713 and Pten.1524 shRNAs served as controls (see Figures S2D–S2F for details).
See also Table S1 and Figure S2.
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recognition and processing, resulting in a substantial increase in
pre-miRNA and mature small RNA levels.
To test the impact of these effects under relevant single-copy
conditions, we transduced NIH 3T3 fibroblasts with single LMP
retroviruses expressing Ren.713 or one of three tested Pten
shRNAs in the miR-30 or miR-E backbone and subsequently
quantified pri-miRNA levels using quantitative RT-PCR (qRT-
PCR), as well as mature miRNA abundance using deep
sequencing of small RNA libraries. For all four shRNAmirs, use
of the miR-E design resulted in a strong reduction of pri-miRNA
levels (Figure 3F) and amassive (7- to 32-fold) increase in mature
small RNA levels (Figure 3G). Although the most striking effects
were observed for Pten.1524, even the potent miR-30 shRNAs
Ren.713 and Pten.1523 yielded ten times more mature small
RNAs when expressed from the miR-E backbone. At the same
time, the absolute level of synthetic small RNAs produced from
miR-E constructs remained well below the most strongly ex-
pressed endogenous miRNAs, and endogenous miRNA abun-
dances were not affected by the use of miR-E backbones
when compared to miR-30 (Pearson r = 0.99). In conjunction
with previous analyses of miR-30 shRNAs (Premsrirut et al.,
2011), these results demonstrate that single-copy expression
of miR-E-based shRNAs has no major effects on endogenous
miRNA biogenesis and thus provides a validated approach for
minimizing toxicities associated with shRNA expression in other
RNAi systems (Castanotto et al., 2007; Grimm et al., 2006).
We also took advantage of our deep-sequencing data set to
analyze the accuracy ofDroshaandDicer processing (Figure 3H).
Drosha cleaved at its canonical site in 25%–70%, whereas a
large fraction of experimental pre-shRNAs resulted from cleav-
age 1–2 nt closer to the loop. Interestingly, while miR-30
and miR-E versions of individual shRNAs resulted in very similar
cleavage patterns, specific shRNAs were associated with strong
biases, suggesting that the synthetic stem sequence affects the
accuracy of the Microprocessor. In stark contrast, Dicer cleaved
experimental pre-miRNAs at the canonical site in 82%–100% of
cases. These dramatic differences between Drosha and Dicer
confirmed our rationale for keeping the experimental guide on
the 30 stem side. Only in this configuration the 50 end of the guide,
which is critical for shRNA seed-sequence determination, strand
selection, and overall potency (Fellmann et al., 2011; Frank et al.,
2010), will be determined by Dicer, whereas the less precise
Drosha cleavage will produce variable 30 guide ends.
DISCUSSION
The miR-30 system is a well-established and commonly used
platform for shRNAmir-based RNAi that has proved its effective-
ness and versatility in countless cell types and experimental set-
tings, ranging from high-throughput screens to transgenic mice.
Here, we have tackled the key limitation of current shRNAmir
reagents—the frequent ineffectiveness of computationally pre-
dicted shRNAmirs to trigger potent knockdown when expressed
under low-or single-copy conditions. Our study identifies
and validates an improved miR-30 backbone termed miR-E,
which generally boosts knockdown potency through strongly
enhanced pri-miRNA processing that leads to 10- to 30-fold
higher mature small RNA levels.Cell ReAs a key feature underlying the improved function of miR-E,
our study identifies an evolutionarily conserved element in-
volving an ACNNC motif 30 of the basal stem and demonstrates
its decisive role for optimal performance of MIR30A-based
shRNAmir reagents. Although our analysis was focused on
experimental applications, a recent study has used an unbiased
high-throughput assay to explore features associated with effec-
tive processing of endogenous pri-miRNAs (Auyeung et al.,
2013). As one out of three sequence features, this study identi-
fied a similar motif (CNNC) at the same position and implicates
it in recruitment of a splicing factor (SRSF3, also known as
SRp20) that appears to be required for optimal pri-miRNA recog-
nition and processing of endogenous miRNAs. Beyond estab-
lishing the relevance of this feature for the design of experimental
shRNAmirs, our study shows that the nucleotide 50 of CNNC can
have a strong impact on pri-miRNA processing, and in endoge-
nousmiRNAs is globally biased against C. The other two features
identified by Auyeung et al. (2013) include a UG at the 50 basal
stem basis and a bias for UGUG at the 50 loop end, which had
a much weaker impact on processing efficiency. Although the
basal UG motif is present in all miR-30 variants, the apical
UGUG has been changed to AGUG in miR-30, and restoring
the original loop indeed moderately improved knockdown
potency of miR-30-based shRNAs (L in Figure 1B). Though we
do not rule out that alternative loops may provide opportunities
to further improve the miR-E design, their implementation in ex-
isting reagents and protocols will be less straightforward and re-
quires more extensive testing.
The simple yet effective nature of miR-E lends itself for direct
implementation in any laboratory performing vector-based
RNAi studies. Importantly, because the design features of
miR-E do not affect the core stem-loop structure, existing miR-
30 shRNAs can be easily converted through PCR subcloning
into the miR-E backbone (Figure 4A), which has already been
implemented in a variety of constitutive andTet-regulated shRNA
expression vectors (Figures 4B, 4C, S4C, and S4D). For de novo
shRNA cloning, combining the superior processing features of
miR-E with optimized Sensor-based shRNA designs (Table S3)
boosts the chances of identifying potent single-copy shRNAs.
Based on our experience with the miR-E backbone, >50% of
top Sensor-based predictions for a given gene trigger >80%pro-
tein knockdown at single copy. In addition to their effectiveness,
Sensor-based shRNAs are characterized by an extreme bias for
loading the intended guide strand (Fellmann et al., 2011) and
therefore provide a means to minimize passenger-mediated
off-target effects. Hence, the combination of Sensor-based pre-
dictions and miR-E opens a promising avenue for generating
focused and genome-wide shRNA libraries that will truly cover
each gene with multiple effective shRNAs, reduce the likelihood
of general and passenger-mediated off-target effects, and
constitute a validated and versatile tool for high-throughput func-
tional genetics in the postgenomic era.EXPERIMENTAL PROCEDURES
Vectors, Backbone, and shRNA Cloning
The miR-E backbone and all variants were constructed according to
sequences provided in Figure S1B using custom oligonucleotides (IDT) andports 5, 1704–1713, December 26, 2013 ª2013 The Authors 1709
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Figure 3. miR-E Enhances Knockdown Potency through Improved shRNA Biogenesis
(A and B) (A) Reporter-assay and (B) NIH 3T3 immunoblotting based evaluation of point mutations in a conserved region 30 of the basal shRNA stem (sequence
shown in black; see Figure 1A for details). Cells were transduced with the indicated control shRNAs or Pten.1524 in backbones containing the shown point
mutations (red) under single-copy conditions. Asterisk, this mutant corresponds to the conventional miR-30 in this region.
(C) Sequence motif analysis in 30 flanks of endogenous human microRNAs. Shown are the relative frequencies of occurrence for the given sequence motifs
(NCNNC) at the indicated positions 30 of the Drosha cleavage site. See Figure S3A for an analysis of 50 flanks; see also Figure S3B and Table S2.
(D) Quantification of GFP fluorescence intensities of cells transduced at single copy with LMN vectors expressing GFP-coupled miR-30 or miR-E shRNAs (see
also Figure S3C). Error bars represent SD.
(E) Schematic showing the dual use of fluorophore-miRNA polycistronic transcripts (pri-miRNA) for both protein synthesis (GFP, mRNA translation) and miRNA
biogenesis (miR-30/miR-E, RNAi pathway). A red box and arrow highlight the region mutated in (A) and (B).
(F) Quantification of pri-miRNA transgene levels in NIH 3T3s expressing the indicated miR-30- or miR-E-based shRNAs from a single-copy genomic integration.
The data show normalized means with error bars indicating the SD of triplicates (see also Figure S3D).
(legend continued on next page)
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Figure 4. Implementation of the miR-E Design
(A) Schematic of PCR-based cloning of existing miR-30 shRNAs, or de novo
synthesized shRNA oligonucleotides, into miR-E recipient vectors to imple-
ment the improved miR-E backbone design.
(B) Validated constitutive retro- and lentiviral miR-E expression vectors, cloned
and tested in various versions featuring different drug selection (Puro/Neo) and
fluorescent (GFP/Cherry) markers (see Figures S3A–S3D for details).
(C) Validated Tet-regulated miR-E expression vectors (all available in a retro-
and lentiviral backbone) expressing fluorescence-coupled miR-E shRNAs
from an optimized Tet-responsive element promoter (T3G), which strongly
reduces leaky shRNA expression. Vector variants harboring rtTA3 feature a
positive feedback loop to boost rtTA3 expression upon dox treatment (Zuber
et al., 2011a) and enable single-vector (‘‘all-in-one’’) Tet-ON shRNAmir
expression studies.
See also Table S3 and Figure S4.standard cloning techniques. Retroviral vectors (Figure S4C) were constructed
based on existing miR-30 shRNA expression vectors in pMSCV or pQCXIX
backbones (Dickins et al., 2005; Zuber et al., 2011a, 2011c); lentiviral vectors
(Figure S4D) were constructed in the pRRL backbone (Dull et al., 1998) based
on derivatives of pRRL.PPT.SF.GFPpre (Schambach et al., 2006). Existing
miR-30 shRNAs were converted to miR-E by simple PCR amplification using
the primers miRE-Xho-short-fw (50-AGAAGGCTCGAGAAGGTATATTGC-30)
and miRE-EcoPlasmid-rev (50-GCTCGAATTCTAGCCCCTTGAAGTCCGA
GG-30), 10 ng plasmid template, and the PfuUltra HF kit (Agilent Technologies),
and amplification products were XhoI/EcoRI cloned into miR-E recipient
vectors. For de novo generation of miR-E shRNAs, 97-mer oligonucleotides
(IDT Ultramers) coding for the respective shRNAs (Table S1) were PCR
amplified using the primers miRE-Xho-fw (50- TGAACTCGAGAAGGTATAT
TGCTGTTGACAGTGAGCG-30) and miRE-EcoOligo-rev (50-TCTCGAATTCT
AGCCCCTTGAAGTCCGAGGCAGTAGGC-30 ), 0.05 ng oligonucleotide tem-(G) Deep-sequencing analysis of mature small RNAs of endogenous mouse mic
RNAs in NIH 3T3s transduced at single copywith LMPexpressing one of four shRN
are means of four replicates. r, Pearson correlation coefficient. Endo miRNAs, en
levels when expressing the indicated shRNAs from miR-E compared to miR-30.
(H) Drosha and Dicer cleavage accuracy for three Pten shRNAs expressed from
position. Cleavage is indicated with respect to the canonical cleavage site (see F
See also Table S2 and Figure S3.
Cell Replate, and the PfuUltra HF kit (Agilent), and cloned into miRE recipient vectors.
More detailed protocols are provided in the Supplemental Information, and all
vectors are available upon request.
Sensor Rules and shRNA Design
For de novo prediction of shRNAs, siRNA guide predictions targeting common
regions of all known transcript variants (NCBI Gene, http://www.ncbi.nlm.nih.
gov/gene/) were obtained using the DSIR algorithm (Vert et al., 2006). DSIR-
predicted guide strands were subsequently filtered using ‘‘Sensor rules’’ to
enrich for predictions harboring sequence features associated with effective
shRNAmir processing and potent knockdown (Fellmann et al., 2011). A com-
plete list of up-to-date Sensor-based shRNA predictions for all human and
mouse coding genes are provided in Table S3.
Cell Culture, Retroviral Transduction, and Reporter Assay for shRNA
Knockdown Quantification
Cell lines were retrovirally transduced under single-copy conditions as previ-
ously described (Fellmann et al., 2011). Competitive proliferation assays
were performed as previously described in Tet-ON competent MOLM-13 cells
(Zuber et al., 2011c). To quantify protein knockdown potency under single-
copy conditions, we established a scalable two-vector/two-color reporter
assay involving a reporter vector (TtNPT) constitutively expressing a hybrid
transcript encoding dTomato (or Ametrine) and harboring up to 20 shRNA
target sites (cloned using IDT gBlocks) in its 30 UTR (Figure S1C). Stable
reporter cells generated using retroviral transduction and selection were sub-
sequently infected at single copy with shRNAmir expression vectors coex-
pressing GFP (e.g., LMP, LEPG, LENG; Figure S1D). dTomato (or Ametrine)
expression was quantified in shRNA expressing (GFP+) cells using flow cytom-
etry after 3–6 days and compared to in-sample GFP control cells, as well as to
parallel samples harboring control shRNAs of known potency (Figures S1C–
S1F). More detailed protocols and additional experimental procedures
(describing qRT-PCR, small RNA sequencing, and immunoblotting analyses)
are provided in the Supplemental Information.
Analysis of Sequence Motif Conservation and microRNA
Representation
Human pre-miRNA and mature miRNA data were obtained from miRbase
(Kozomara and Griffiths-Jones, 2011), release 20. All pre-miRNAs were
extended by 100 nt on each side by alignment to the genome. Drosha cleavage
sites were determined by matching the mature miRNAs to the corresponding
pre-miRNAs (842 miRNAs with annotated sense and antisense strand).
MicroRNAs where the start of the sense and antisense were >60 nt apart
(22) were eliminated, leaving 820 human miRNAs for analysis. Mature small
RNA sequencing data of HEK293T were generated previously (Fellmann
et al., 2011) and reanalyzed by alignment to the human mature miRNA collec-
tion. For miRNA representation analyses, only the guide strands (miR strand,
defined by the higher read count) were used; 515 such miRNA guide strands
were identified that had reads in HEK293T cells as well as an annotated sense
and antisense strand.
Statistical Analysis
Linear dependence of variables was evaluated using the Pearson product-
moment correlation coefficient r. Measurement predictability is given by error
bars indicating the standard error of the mean (SEM) of biologically indepen-
dent triplicates. Unless otherwise indicated, p values were calculated using
an unpaired t test. Significance of differential miRNA representation between
classes with or without a certain sequence motif was assessed using theroRNAs and synthetic shRNAs. Compared are read numbers of mature small
As from eithermiR-E (y axis) ormiR-30 (x axis). Values for endogenousmiRNAs
dogenous microRNAs. The inset shows the fold change in mature small RNA
either miR-30 or miR-E. Shown are the guide strand read fractions at each
igure 1A for details).
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Wilcoxon-Mann-Whitney U test, with Sida´k correction to adjust for inflation of
the a level due to large sample sets.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and three tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2013.11.020.
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